<?xml version="1.0" encoding="UTF-8"?>
<!-- generator="wordpress/2.2.2" -->
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	>

<channel>
	<title>VIX Trade</title>
	<link>http://vixtrade.com</link>
	<description>trade options on the vix index</description>
	<pubDate>Thu, 24 Jul 2008 14:18:51 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.2.2</generator>
	<language>en</language>
			<item>
		<title>GE’s inorganic growth</title>
		<link>http://vixtrade.com/2008/07/24/ge%e2%80%99s-inorganic-growth/</link>
		<comments>http://vixtrade.com/2008/07/24/ge%e2%80%99s-inorganic-growth/#comments</comments>
		<pubDate>Thu, 24 Jul 2008 14:18:51 +0000</pubDate>
		<dc:creator></dc:creator>
		
		<category><![CDATA[options news]]></category>

		<category><![CDATA[stock news]]></category>

		<guid isPermaLink="false">http://vixtrade.com/2008/07/24/ge%e2%80%99s-inorganic-growth/</guid>
		<description><![CDATA[General Electric has bulked up on its health binge, moving to buy medical device maker Vital Signs for $860 million. Vital Signs shareholders are to get $74.50 per share in cash, a 28.4 percent premium to Wednesday&#8217;s closing price, and above the shares&#8217; 52-week high of $61.20, reached on May 9. GE said the deal, [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://blogs.reuters.com/reuters-dealzone/files/2008/07/ge2.jpg" title="General Electric’s Jeffrey R. Immelt in a file photo."><img src="http://blogs.reuters.com/reuters-dealzone/files/2008/07/ge2.jpg" alt="General Electric’s Jeffrey R. Immelt in a file photo." align="left" height="71" width="100" /></a><strong>General Electric </strong>has bulked up on its health binge, moving to <a href="http://www.reuters.com/article/innovationNews/idUSN2450149920080724">buy<strong> </strong>medical device maker Vital Signs for $860 million. </a>Vital Signs shareholders are to get $74.50 per share in cash, a 28.4 percent premium to Wednesday&rsquo;s closing price, and above the shares&rsquo; 52-week high of $61.20, reached on May 9. GE said the deal, which it expects to close in the fourth quarter, values Vital Signs at $860 million, net of cash and investments. It said that shareholders with a 37 percent stake in Vital Signs have agreed to vote in favor of the deal.</p>
<p>Chinese pickup truck maker <strong>Hebei Zhongxing Automobile Co</strong> is in talks with <strong>General Motors</strong> and major Chinese automaker <strong>FAW Group</strong> to <a href="http://www.reuters.com/article/rbssAutoTruckManufacturers/idUSSHA1941620080724">explore opportunities for cooperation, </a>including possible equity ties, a source close to the situation said. &ldquo;Consolidation is inevitable in the Chinese auto market, which now has more than 100 players, and a company of Zhongxing&rsquo;s size makes a good takeover target or joint venture partner,&rdquo; the source told Reuters. &ldquo;Zhongxing is holding talks with several potential partners including FAW and GM to seek cooperative opportunities, including possible equity ties, but nothing has been decided at the moment,&rdquo; a source said.</p>
<p><strong>Tribune</strong> has <a href="http://www.reuters.com/article/ousivMolt/idUSN2328665720080724">narrowed the potential list of bidders </a>for the storied Chicago Cubs baseball team to 3-5 groups bidding $1 billion or more, according to sources briefed on the matter. Of the 10 groups approved to bid for the Cubs by Major League Baseball, only those that bid $1 billion or more for the team, its home ballpark Wrigley Field and a stake in a regional sports TV network advanced to the next round, said two sources, who asked not to be identified because the process is ongoing. While Tribune and baseball officials declined to comment, three sources said Internet billionaire Mark Cuban, owner of the National Basketball Association Dallas Mavericks; and a publicly held group led by New York City taxi tycoon Andrew Murstein were among those advancing. Others advancing included Tom Ricketts, chief executive of <strong>Incapital</strong> LLC, a Chicago securities and investment banking firm, and son of the founder of <strong>TD Ameritrade</strong>; and a group headed by Michael Tokarz, chairman of <strong>MVC Capital</strong>, one of the sources said. The Tokarz group includes Fred Malek, who previously bid on the baseball team in Washington.</p>
<p>Other deals of the day:</p>
<p>* The head of state-run <strong>Korea Development Bank</strong> said it would resume the delayed sale of <strong>Daewoo Shipbuilding</strong> in August, possibly wrapping up the $4 billion deal by end-2008.</p>
<p>* South Korea&rsquo;s <strong>Hana Financial Group</strong>, the country&rsquo;s No.4 banking group, said its banking unit would invest 329.6 billion won ($327 million) to take a 19.7 percent stake in the <strong>Bank of Jilin</strong> in China.</p>
<p>* Malaysia&rsquo;s <strong>Maybank</strong> is set to buy another 5 percent of Pakistan&rsquo;s <strong>MCB Bank</strong> as early as next month, in a deal estimated at $218 million, sources familiar with the matter said on Thursday.</p>
<p>* <strong>Intel Capital</strong>, the venture capital arm of top chipmaker <strong>Intel</strong> <strong>Corp</strong>, said it would pump $17 million into three Indian companies, comprising two Internet portals and one advertising firm.</p>
<p>* <strong>Mapletree Investments</strong>, a property firm owned by Singapore state investor <strong>Temasek</strong>, said it will support a rights issue by <strong>Mapletree Logistics Trust</strong> by buying units not taken up by other investors.</p>
<div>
<a href="http://feeds.reuters.com/~f/reuters/blogs/reuters-dealzone?a=nBXAvj"><img src="http://feeds.reuters.com/~f/reuters/blogs/reuters-dealzone?i=nBXAvj" border="0"></img></a> <a href="http://feeds.reuters.com/~f/reuters/blogs/reuters-dealzone?a=8NU8xj"><img src="http://feeds.reuters.com/~f/reuters/blogs/reuters-dealzone?i=8NU8xj" border="0"></img></a> <a href="http://feeds.reuters.com/~f/reuters/blogs/reuters-dealzone?a=dVIMLj"><img src="http://feeds.reuters.com/~f/reuters/blogs/reuters-dealzone?i=dVIMLj" border="0"></img></a>
</div>
<p><img src="http://feeds.reuters.com/~r/reuters/blogs/reuters-dealzone/~4/344613733" height="1"></p>
]]></content:encoded>
			<wfw:commentRss>http://vixtrade.com/2008/07/24/ge%e2%80%99s-inorganic-growth/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Turning the Glaxo supertanker</title>
		<link>http://vixtrade.com/2008/07/24/turning-the-glaxo-supertanker/</link>
		<comments>http://vixtrade.com/2008/07/24/turning-the-glaxo-supertanker/#comments</comments>
		<pubDate>Thu, 24 Jul 2008 14:18:43 +0000</pubDate>
		<dc:creator></dc:creator>
		
		<category><![CDATA[options news]]></category>

		<category><![CDATA[stock news]]></category>

		<guid isPermaLink="false">http://vixtrade.com/2008/07/24/turning-the-glaxo-supertanker/</guid>
		<description><![CDATA[Diversification is the buzz word in pharmaceuticals as the feared 2010-2012 patent &#8220;cliff&#8221; looms nearer, when many of world&#8217;s top medicines lose patent protection.
New Glaxo CEO Andrew Witty, 43, is embracing the concept wholeheartedly via a bold deal with South Africa&#8217;s Aspen that takes the world&#8217;s second biggest drugmaker into generics in emerging markets and a strategy to broaden [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://blogs.reuters.com/globalinvesting/files/2008/07/witty-july-2008.jpg" title="witty-july-2008.jpg"><img align="left" width="203" src="http://blogs.reuters.com/globalinvesting/files/2008/07/witty-july-2008.jpg" alt="witty-july-2008.jpg" height="300" /></a>Diversification is the buzz word in pharmaceuticals as the feared 2010-2012 patent &#8220;cliff&#8221; looms nearer, when many of world&#8217;s top medicines lose patent protection.</p>
<p>New Glaxo CEO Andrew Witty, 43, is embracing the concept wholeheartedly via a bold <a href="http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10086.htm">deal</a> with South Africa&#8217;s Aspen that takes the world&#8217;s second biggest drugmaker into generics in emerging markets and a <a href="http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10088.htm">strategy</a> to broaden out the group.</p>
<p>But how long will Glaxo&#8217;s not-so-patient shareholders have to wait to reap the rewards?</p>
<p>Witty gave a confident performance during a two-hour meeting with analysts this week, but a sliding share price the day after suggests investors see little to cheer about just yet.</p>
<p>Investing for diversity to de-risk the business may make sense, but bulking up in non-prescription healthcare products, vaccines, biotech and emerging markets will take time &#8211; as well as money, as evidenced by the decision to delay completion of the company&#8217;s 12 billion pounds buyback programme.</p>
<p>&#8220;You can&#8217;t turn a supertanker on a dime,&#8221; says Deutsche Bank analyst Brian Bourdot.</p>
<div>
<a href="http://feeds.reuters.com/~f/reuters/blogs/reuters-dealzone?a=hXrDPj"><img src="http://feeds.reuters.com/~f/reuters/blogs/reuters-dealzone?i=hXrDPj" border="0"></img></a> <a href="http://feeds.reuters.com/~f/reuters/blogs/reuters-dealzone?a=BjHPUj"><img src="http://feeds.reuters.com/~f/reuters/blogs/reuters-dealzone?i=BjHPUj" border="0"></img></a> <a href="http://feeds.reuters.com/~f/reuters/blogs/reuters-dealzone?a=2nitFj"><img src="http://feeds.reuters.com/~f/reuters/blogs/reuters-dealzone?i=2nitFj" border="0"></img></a>
</div>
<p><img src="http://feeds.reuters.com/~r/reuters/blogs/reuters-dealzone/~4/344602337" height="1"></p>
]]></content:encoded>
			<wfw:commentRss>http://vixtrade.com/2008/07/24/turning-the-glaxo-supertanker/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Lehman’s fortune-tellers</title>
		<link>http://vixtrade.com/2008/07/24/lehman%e2%80%99s-fortune-tellers/</link>
		<comments>http://vixtrade.com/2008/07/24/lehman%e2%80%99s-fortune-tellers/#comments</comments>
		<pubDate>Thu, 24 Jul 2008 14:18:29 +0000</pubDate>
		<dc:creator></dc:creator>
		
		<category><![CDATA[options news]]></category>

		<category><![CDATA[stock news]]></category>

		<guid isPermaLink="false">http://vixtrade.com/2008/07/24/lehman%e2%80%99s-fortune-tellers/</guid>
		<description><![CDATA[Yesterday, UBS put out a research note saying Lehman was likely to make a sizeable asset sale, which may include the disposition of its investment management unit Neuberger Berman.
Today, Morgan Stanley said in a research note that although the bank may make a &#8220;meaningful&#8221; asset disposition, it was unlikely to sell Neuberger.
This apparent contradiction isn&#8217;t [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://blogs.reuters.com/reuters-dealzone/files/2008/07/fortune.jpg" title="fortune.jpg"><img align="left" width="300" src="http://blogs.reuters.com/reuters-dealzone/files/2008/07/fortune.jpg" alt="fortune.jpg" height="189" /></a>Yesterday, UBS put out a <a href="http://www.reuters.com/article/ousivMolt/idUSBNG31385520080723">research note</a> saying Lehman was likely to make a sizeable asset sale, which may include the disposition of its investment management unit Neuberger Berman.</p>
<p>Today, Morgan Stanley <a href="http://www.reuters.com/article/innovationNews/idUSBNG17321920080724">said in a research note </a>that although the bank may make a &ldquo;meaningful&rdquo; asset disposition, it was unlikely to sell Neuberger.</p>
<p>This apparent contradiction isn&rsquo;t the first, let&rsquo;s say, difference of opinion among analysts, reporters, lawyers, bankers and other Wall Street mandarins who have waxed eloquent and written reams on the fate of Lehman, the smallest surviving major independent Wall Street investment bank after the near collapse and takeover of Bear Stearns.</p>
<p>Last week&rsquo;s flavour was a debate over whether Lehman would go private after a <a href="http://blogs.reuters.com/reuters-dealzone/2008/07/14/go-private-to-avoid-the-short-sighted/">Fox-Pitt Kelton analyst said that may be the best course of action</a> for the brokerage and the <a href="http://www.reuters.com/article/rbssInvestmentServices/idUSBNG27828420080715">New York Post reported that the investment bank was indeed weighing such an option</a>. The idea was quickly shot down in a series of articles, research notes and such that rattled off a host of problems with it.</p>
<p>At least some of Lehman&rsquo;s issues may just be phantom problems dreamed up by speculators, one investment banker said last week.</p>
<p>&ldquo;Like the market knows more than the management team and auditors of Lehman Brothers? How&rsquo;s that possible? What do they know? They don&rsquo;t know sh*t,&rdquo; the banker said. &ldquo;I am not here to defend Lehman. But let&rsquo;s get real.&rdquo; </p>
<p>Still, many of the notes and reports are considered opinions from people who one would suspect do understand a thing or two about how the business works.</p>
<p>And the difference in opinion about the best way forward could very well illustrate the problem Lehman Chief Dick Fuld and his team are facing today &mdash; there are no easy solutions before the investment bank.</p>
<p>So what do you think Lehman will do?</p>
<p>(Photo: This Reuters picture shows a Sotheby&rsquo;s employee look at &rdquo;Fortune Teller,&rdquo; a painting by late Swiss artist Albert Anker.)</p>
<div>
<a href="http://feeds.reuters.com/~f/reuters/blogs/reuters-dealzone?a=107Sxj"><img src="http://feeds.reuters.com/~f/reuters/blogs/reuters-dealzone?i=107Sxj" border="0"></img></a> <a href="http://feeds.reuters.com/~f/reuters/blogs/reuters-dealzone?a=MRQhFj"><img src="http://feeds.reuters.com/~f/reuters/blogs/reuters-dealzone?i=MRQhFj" border="0"></img></a> <a href="http://feeds.reuters.com/~f/reuters/blogs/reuters-dealzone?a=2geaYj"><img src="http://feeds.reuters.com/~f/reuters/blogs/reuters-dealzone?i=2geaYj" border="0"></img></a>
</div>
<p><img src="http://feeds.reuters.com/~r/reuters/blogs/reuters-dealzone/~4/344571799" height="1"></p>
]]></content:encoded>
			<wfw:commentRss>http://vixtrade.com/2008/07/24/lehman%e2%80%99s-fortune-tellers/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Another Blow To Microsoft&#8217;s Online Ambitions: Umpteenth Reorg and Kevin Johnson To Juniper</title>
		<link>http://vixtrade.com/2008/07/24/another-blow-to-microsofts-online-ambitions-umpteenth-reorg-and-kevin-johnson-to-juniper/</link>
		<comments>http://vixtrade.com/2008/07/24/another-blow-to-microsofts-online-ambitions-umpteenth-reorg-and-kevin-johnson-to-juniper/#comments</comments>
		<pubDate>Thu, 24 Jul 2008 08:10:13 +0000</pubDate>
		<dc:creator></dc:creator>
		
		<category><![CDATA[stock news]]></category>

		<guid isPermaLink="false">http://vixtrade.com/2008/07/24/another-blow-to-microsofts-online-ambitions-umpteenth-reorg-and-kevin-johnson-to-juniper/</guid>
		<description><![CDATA[From Silicon Alley Insider, July 23, 2008:
The head of Microsoft&#8217;s Platforms and Services Business (which includes the online business), Kevin Johnson, is
]]></description>
			<content:encoded><![CDATA[<p>From Silicon Alley Insider, July 23, 2008:</p>
<p>The head of Microsoft&#8217;s Platforms and Services Business (which includes the online business), Kevin Johnson, is</p>
]]></content:encoded>
			<wfw:commentRss>http://vixtrade.com/2008/07/24/another-blow-to-microsofts-online-ambitions-umpteenth-reorg-and-kevin-johnson-to-juniper/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Amazon Q2: Revenue In Line, EPS Boosted By One-Time Gain (AMZN)*</title>
		<link>http://vixtrade.com/2008/07/24/amazon-q2-revenue-in-line-eps-boosted-by-one-time-gain-amzn/</link>
		<comments>http://vixtrade.com/2008/07/24/amazon-q2-revenue-in-line-eps-boosted-by-one-time-gain-amzn/#comments</comments>
		<pubDate>Thu, 24 Jul 2008 08:10:07 +0000</pubDate>
		<dc:creator></dc:creator>
		
		<category><![CDATA[stock news]]></category>

		<guid isPermaLink="false">http://vixtrade.com/2008/07/24/amazon-q2-revenue-in-line-eps-boosted-by-one-time-gain-amzn/</guid>
		<description><![CDATA[From Silicon Alley Insider, July 23, 2008:
Release out: Solid quarter in a weak economy. Revenue in line, EPS through roof once including a $53 million one time non-cash gain from the sale of a European DVD business. &#8230;
]]></description>
			<content:encoded><![CDATA[<p>From Silicon Alley Insider, July 23, 2008:</p>
<p>Release out: Solid quarter in a weak economy. Revenue in line, EPS through roof once including a $53 million one time non-cash gain from the sale of a European DVD business. &#8230;</p>
]]></content:encoded>
			<wfw:commentRss>http://vixtrade.com/2008/07/24/amazon-q2-revenue-in-line-eps-boosted-by-one-time-gain-amzn/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Bouncing Banks: How $11B of Losses Is &#8216;Good News&#8217; on Wall St.</title>
		<link>http://vixtrade.com/2008/07/24/bouncing-banks-how-11b-of-losses-is-good-news-on-wall-st-2/</link>
		<comments>http://vixtrade.com/2008/07/24/bouncing-banks-how-11b-of-losses-is-good-news-on-wall-st-2/#comments</comments>
		<pubDate>Thu, 24 Jul 2008 08:10:02 +0000</pubDate>
		<dc:creator></dc:creator>
		
		<category><![CDATA[stock news]]></category>

		<guid isPermaLink="false">http://vixtrade.com/2008/07/24/bouncing-banks-how-11b-of-losses-is-good-news-on-wall-st-2/</guid>
		<description><![CDATA[Financial stocks were taking a breather Wednesday, which is to be expected after the group&#8217;s ferocious rally. Heading into today, the Financial SPDR (XLF) had risen 31% in a five-day advance, culminating (perhaps) on Tuesday when huge losses were greeted
]]></description>
			<content:encoded><![CDATA[<p>Financial stocks were taking a breather Wednesday, which is to be expected after the group&#8217;s ferocious rally. Heading into today, the Financial SPDR (XLF) had risen 31% in a five-day advance, culminating (perhaps) on Tuesday when huge losses were greeted</p>
]]></content:encoded>
			<wfw:commentRss>http://vixtrade.com/2008/07/24/bouncing-banks-how-11b-of-losses-is-good-news-on-wall-st-2/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Housing Bill: Better Than Nothing, But No Cure for Still-Ailing Market</title>
		<link>http://vixtrade.com/2008/07/24/housing-bill-better-than-nothing-but-no-cure-for-still-ailing-market-2/</link>
		<comments>http://vixtrade.com/2008/07/24/housing-bill-better-than-nothing-but-no-cure-for-still-ailing-market-2/#comments</comments>
		<pubDate>Thu, 24 Jul 2008 08:09:48 +0000</pubDate>
		<dc:creator></dc:creator>
		
		<category><![CDATA[stock news]]></category>

		<guid isPermaLink="false">http://vixtrade.com/2008/07/24/housing-bill-better-than-nothing-but-no-cure-for-still-ailing-market-2/</guid>
		<description><![CDATA[For months, America&#8217;s politicians fiddled over housing legislation as the real estate market burned. This week, after a full-court press from Treasury Secretary Paulson and others, Congress is expected to pass related legislation.Key points of the bill, w
]]></description>
			<content:encoded><![CDATA[<p>For months, America&#8217;s politicians fiddled over housing legislation as the real estate market burned. This week, after a full-court press from Treasury Secretary Paulson and others, Congress is expected to pass related legislation.Key points of the bill, w</p>
]]></content:encoded>
			<wfw:commentRss>http://vixtrade.com/2008/07/24/housing-bill-better-than-nothing-but-no-cure-for-still-ailing-market-2/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Jobs&#8217; Health Not Private: CEO Had Surgery but No Recurrence of Cancer, says NYT</title>
		<link>http://vixtrade.com/2008/07/24/jobs-health-not-private-ceo-had-surgery-but-no-recurrence-of-cancer-says-nyt-2/</link>
		<comments>http://vixtrade.com/2008/07/24/jobs-health-not-private-ceo-had-surgery-but-no-recurrence-of-cancer-says-nyt-2/#comments</comments>
		<pubDate>Thu, 24 Jul 2008 05:09:39 +0000</pubDate>
		<dc:creator></dc:creator>
		
		<category><![CDATA[stock news]]></category>

		<guid isPermaLink="false">http://vixtrade.com/2008/07/24/jobs-health-not-private-ceo-had-surgery-but-no-recurrence-of-cancer-says-nyt-2/</guid>
		<description><![CDATA[Despite Apple&#8217;s claims to the contrary, Steve Jobs&#8217; health is not a &#8220;private matter.&#8221;That fact has been on display again this week as rumors about Jobs&#8217; health continued to circulate. In the wake of those rumors and various reports in other news
]]></description>
			<content:encoded><![CDATA[<p>Despite Apple&#8217;s claims to the contrary, Steve Jobs&#8217; health is not a &#8220;private matter.&#8221;That fact has been on display again this week as rumors about Jobs&#8217; health continued to circulate. In the wake of those rumors and various reports in other news</p>
]]></content:encoded>
			<wfw:commentRss>http://vixtrade.com/2008/07/24/jobs-health-not-private-ceo-had-surgery-but-no-recurrence-of-cancer-says-nyt-2/feed/</wfw:commentRss>
		</item>
	</channel>
</rss>
